Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Desensitization, Immunologic;Kidney Transplantation, Date of authorisation: 25/08/2020, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Desensitization, Immunologic;Kidney Transplantation, Date of authorisation: 25/08/2020, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Soft Tissue Infections;Skin Diseases, Bacterial, Date of authorisation: 19/02/2015, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Soft Tissue Infections;Skin Diseases, Bacterial, Date of authorisation: 19/02/2015, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Idiopathic Pulmonary Fibrosis, Date of authorisation: 14/01/2015, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Idiopathic Pulmonary Fibrosis, Date of authorisation: 14/01/2015, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Bydureon, exenatide, Diabetes Mellitus, Type 2, Date of authorisation: 17/06/2011, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Bydureon, exenatide, Diabetes Mellitus, Type 2, Date of authorisation: 17/06/2011, Revision: 25, Status: Authorised

FDIME Announces Research Grants in 2023

The Foundation for the Development of Internal Medicine in Europe (FDIME) is offering Research Grants to Young Internists (up to age 38 yrs) to study in:
Research projects including all fields of General Internal Medicine, particularly polymorbidity and other common Interna Medicine conditions.

For details check the FDIME Research Grants webpage at www.fdime.org

OR

Download the Internal Medicine Grant Announcement and Application Form below.

For further information:

EFIM Annual Report 2022

We are proud to present you with the most significant achievements of 2022 published in EFIM Annual Report!
EFIM Annual report showcases important milestones in 2022, achievements of the WGs, collaboration with our partners and stakeholders allowing all our members to explore each activitiy of EFIM through additional documents, and infographics!

Enjoy reading EFIM Annual Report 2022!

8th EFIM Day - 13 October Brussels

It is our great pleasure and honour to announce that the following EFIM Day will take place once again face to face in Brussels close to our Headquarter on Friday 13 October .
We would like to extent an invitation to the Presidents, the Board Members and the Young Internists of EFIM National Societies to join EFIM in discussing different Internal Medicine’s topics on a European level including EFIM new projects and current activities.

EFIM Exchange Programme is Full for 2023!

Due to increased number of Exchange programme applications, we kindly inform you that the 10 bursaries offered by EFIM and FDIME are already in use for 2023 Exchange Programme !
We are happy to process any further applications for the EFIM Exchange Programme in 2023 with the support of your national societies but without EFIM bursary.
Thank you for your understanding!

We are pleased to inform you that EFIM Exchange Programme is open with updated list of hospital centres across Europe.

Survey on Point of Care Ultrasound in Internal Medicine in Europe

Dear EFIM Coleagues, Dear EFIM Members: 

Point of Care Ultrasound is a very useful tool for internists. In the recent years more and more physicians (including Internal Medicine specialists) are incorporating “insonation” in their daily practice.
The EFIM Ultrasound Working Group has prepared a short survey with the following objectives:  

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.